ZIOPHARM Oncology Inc (ZIOP) Shares are Down -2.26%

ZIOPHARM Oncology Inc (ZIOP) has risen sharply, recording gains of 13.97% in the past 4 weeks. However, the stock has corrected -2.26% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 14.58% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 3.63% and the 50-Day Moving Average is 6.21%.The 200 Day SMA reached 14.57%

ZIOPHARM

ZIOPHARM Oncology Inc (NASDAQ:ZIOP): After opening at $5.61, the stock dipped to an intraday low of $5.54 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $5.755 and the buying power remained strong till the end. The stock closed at $5.63 for the day, a gain of 0.90% for the day session. The total traded volume was 1,280,939. The stocks close on the previous trading day was $5.63.

ZIOPHARM Oncology Inc (ZIOP) : The highest short term price target forecast on ZIOPHARM Oncology Inc (ZIOP) is $21 and the lowest target price is $7. A total of 2 equity analysts are currently covering the company. The average price of all the analysts is $14 with a standard deviation of $9.9.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.